Mount Sinai Tisch Cancer Center | Strategic Alliance Partners

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer.

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Miriam Merad, MD, PhD, discusses how her explorations of the role of inflammation in patients with cancer translated into critical insights for patients with COVID-19.

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Ajai Chari, MD, discusses the recent approval of belantamab mafodotin in relapsed/refractory multiple myeloma and other emerging agents under exploration in the space.

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma. 

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.